- Home
- GRPN vs CRVS Comparison
GRPN vs CRVS Comparison
Compare GRPN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRPN
- CRVS
- Stock Information
- Founded
- GRPN 2008
- CRVS 2014
- Country
- GRPN United States
- CRVS United States
- Employees
- GRPN N/A
- CRVS N/A
- Industry
- GRPN Advertising
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GRPN Consumer Discretionary
- CRVS Health Care
- Exchange
- GRPN Nasdaq
- CRVS Nasdaq
- Market Cap
- GRPN 473.0M
- CRVS 516.0M
- IPO Year
- GRPN 2011
- CRVS 2016
- Fundamental
- Price
- GRPN $11.57
- CRVS $4.13
- Analyst Decision
- GRPN Hold
- CRVS Buy
- Analyst Count
- GRPN 3
- CRVS 4
- Target Price
- GRPN $17.00
- CRVS $12.83
- AVG Volume (30 Days)
- GRPN 1.6M
- CRVS 765.4K
- Earning Date
- GRPN 11-12-2024
- CRVS 11-12-2024
- Dividend Yield
- GRPN N/A
- CRVS N/A
- EPS Growth
- GRPN N/A
- CRVS N/A
- EPS
- GRPN 0.52
- CRVS N/A
- Revenue
- GRPN $499,894,000.00
- CRVS N/A
- Revenue This Year
- GRPN N/A
- CRVS N/A
- Revenue Next Year
- GRPN $0.32
- CRVS N/A
- P/E Ratio
- GRPN $21.79
- CRVS N/A
- Revenue Growth
- GRPN N/A
- CRVS N/A
- 52 Week Low
- GRPN $7.75
- CRVS $1.30
- 52 Week High
- GRPN $19.56
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GRPN 56.21
- CRVS 23.60
- Support Level
- GRPN $11.23
- CRVS $7.88
- Resistance Level
- GRPN $13.19
- CRVS $7.44
- Average True Range (ATR)
- GRPN 0.83
- CRVS 0.55
- MACD
- GRPN 0.06
- CRVS -0.34
- Stochastic Oscillator
- GRPN 59.56
- CRVS 2.77
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).